Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus

American Journal of Gastroenterology

Volumn 92, Issue 4, 1997, Pages 582-585

  Sharma, Prateek ^a   Sampliner, Richard E ^a,b   Camargo, Elizabeth ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; ESOPHAGUS MUCOSA; ESOPHAGUS PH; HISTOPATHOLOGY; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; BARRETT ESOPHAGUS; BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGOSCOPY; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS; REMISSION INDUCTION;

EID: 0030947026     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Spechler SJ, Goyal RK. Barrett's esophagus. N Engl J Med 1986;315: 362-71.
2. Winters C, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus: A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987;92:118-24.
3. Bozymski EM, Herlihy KJ, Orlando RC. Barrett's esophagus. Ann Intern Med 1982;97:103-7.
4. Sjorgren RW, Johnson LF. Barret's esophagus: A review. Am J Med 1983;74:313-20.
5. Mulholland MW, Reid BJ, Levine DS, et al. Elevated gastric acid secretion in patients with Barrett's metaplastic epithelium. Dig Dis Sci 1989;34:1329-35.
6. Collen MJ, Lewis JH, Benjamin SB. Gastric acid hypersecretion in refractory gastroesophageal reflux disease. Gastroenterology 1990;98: 654-61.
7. Sampliner RE. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am J Gastroenterol 1994;89:1844-8.
8. Katzka DA, Castell DO. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1994;89:989-91.
9. Sampliner RE, Garewal HS, Fennerty MB, et al. Lack of impact of therapy on extent of Barrett's esophagus in 67 patients. Dig Dis Sci 1990;35:93-6.
10. Johnson LF, DeMeester TR. Twenty-four hour pH monitoring of the distal esophagus: A quantitative measure of gastroesophageal reflux. Am J Gastroenterol 1974;62:325-32.
11. Wellinger J, Ollyo JB, Savary M, et al. Le traitment chirurgical de l'endobrachy-oesophage. Helv Chir Acta 1988;55:695-8.
12. Williamson WA, Ellis FH, Gibb SP, et al. Effective anti-reflux operation on Barrett's mucosa. Ann Thorac Surg 1990;49:537-42.
13. Sagar PM, Ackroyd R, Hosie KB, et al. Regression and progression of Barrett's oesophagus after anti-reflux surgery. Br J Surg 1995;82:806-10.
14. Hamilton SR, Hutcheon DF, Ravich WJ, et al. Adenocarcinoma in Barrett's esophagus after elimination of gastroesophageal reflux. Gastroenterology 1984;86:356-60.
15. Sampliner RE, Steinbronn K, Garewal HS, et al. Squamous mucosa overlying columnar epithelium in Barrett's esophagus in the absence of anti-reflux surgery. Am J Gastroenterol 1988;83:510-2.
16. Gore S, Healey CJ, Sutton R, et al. Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 1993;7:623-8.
17. Neumann CS, Iqbal TH, Cooper BT. Long term continuous omeprazole treatment of patients with Barrett's oesophagus. Aliment Pharmacol Ther 1995;9:451-4.
18. Skinner DB, Walther BC, Riddell RH, et al. Barrett's esophagus: Comparison of benign and malignant cases. Ann Surg 1983;198:554-66.
19. Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1267-89.
20. Pera M, Cameron AJ, Trastek VF, et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993;104:510-3.